Ciltacabtagene autoleucel, an investigational BCMA-directed CAR-T therapy, sustained efficacy and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma.
Recent Content
- Targeting RNA polymerase I to boost natural killer cell anticancer activity in multiple myeloma
- The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience
- (no title)
- New center promotes advocacy for gynecological cancer patients
- FDA clears Thermo Fisher EXTENT system for myeloma diagnosis
- Microbiome modulation uncouples efficacy and toxicity induced by immune checkpoint blockade in mouse multiple myeloma
- TSCM-predominant allogeneic anti-BCMA CAR-T therapy for relapsed/refractory multiple myeloma: preclinical characterization and interim results from a phase 1 trial
- (no title)
- (no title)
- New ‘powerful’ lab test will help researchers explore blood cancer